Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma [Phase 2]
Phase 2 clinical trial evaluating belantamab mafodotin for relapsed/refractory multiple myeloma; status is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) [Phase 1]
This document provides an update on a Phase 1 dose-escalation trial of cevostamab in participants with relapsed or refractory multiple myelo…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) [Phase 2]
Phase 2 trial of pomalidomide in combination with dexamethasone in multiple myeloma patients with Del(17p) or t(4;14) abnormalities; the stu…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET [EARLY_Phase 1]
Early-phase clinical trial evaluating in-human CXCR4 imaging with [68Ga]-Pentixafor-PET in hematologic and solid tumors; the study is curren…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy [Phase 3]
Phase 3 extension trial update for Total Therapy 3B in multiple myeloma; the study (UARK 2006-66) is active but not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy [NA]
Clinical Trial Update describes a recruiting study at the University of Utah evaluating multimodal telerehabilitation for patients undergoin…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
A recruiting clinical trial aims to predict progression to multiple myeloma in high-risk screened individuals and the general population.
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Exercise Therapy for Multiple Myeloma Patients [NA]
A clinical trial is studying exercise therapy for patients with multiple myeloma and bone lesions, and it is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) [Phase 3]
Phase 3 trial evaluating isatuximab added to RVd induction and lenalidomide maintenance for newly diagnosed multiple myeloma; currently acti…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial [Phase 2]
This entry describes the REACH trial, a Phase 2 study of combination therapy approaches for high-risk multiple myeloma, currently active but…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
This completed clinical trial evaluated comprehensive geriatric assessment and laboratory biomarkers in elderly patients with multiple myelo…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating alternate dosing schedules of belantamab mafodotin for triple-class refractory multiple myeloma; recruit…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
This document describes an ongoing Phase 1/2 clinical trial to determine the recommended dose and schedule and assess safety and preliminary…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. [Phase 2]
An update on an ongoing Phase 2 trial studying selinexor with low-dose dexamethasone in penta-refractory multiple myeloma, and selinexor wit…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies [Phase 1]
A Phase 1 clinical trial evaluating the combination of Elotuzumab, CC-92480, and Dexamethasone in relapsed or refractory multiple myeloma af…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 clinical trial comparing iberdomide alone versus iberdomide plus isatuximab as maintenance therapy after autologous stem cell tran…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Venetoclax
Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, A…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Phase I Trial of VS-6766 Alone and in Combination With Everolimus [Phase 1]
Completed Phase I trial evaluating VS-6766 alone and in combination with everolimus in patients with solid tumors, multiple myeloma, lung ca…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM [Phase 1]
This document summarizes a Phase 1 clinical trial update evaluating a DC/MM fusion vaccine in combination with BCMA-targeted CAR-T therapy f…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 3]
This clinical trial update describes a Phase 3 study evaluating SCTC21C in combination with bortezomib, lenalidomide and dexamethasone for n…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma [NA]
A clinical trial from Universidad Complutense de Madrid is studying whether controlled breathing has measurable effects on cardiorespiratory…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) [Phase 2]
Phase 2 clinical trial evaluating BCMA-targeted bispecific antibody therapy for multiple myeloma patients who relapse after BCMA CAR T-cell …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment [NA]
A clinical study evaluating a BCMA-GPRC5D CAR-T therapy for relapsed/refractory multiple myeloma is listed, but the trial is not yet recruit…
-
EMA approval · 2026-01-28EMA Authorised: Pomalidomide Teva (Pomalidomide) — Teva GmbH
EMA has authorised Teva GmbH's pomalidomide product for the treatment of multiple myeloma; decision date 28 January 2026.
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics [NA]
This entry reports a recruiting trial at UNC Lineberger Comprehensive Cancer Center evaluating a decision-support tool for adults with hemat…